Integral develops advanced technologies for treating neurological and psychiatric disorders. Their initial product is a miniaturized, implanted deep-brain interface capable of high-fidelity neural recording and modulation. This platform aims to significantly improve treatment efficacy for brain disorders and accelerate biological understanding.
Funding
Funding not disclosed
Founders
Product
Problem
Neurological and psychiatric disorders often require precise monitoring and modulation of neural activity, but current deep-brain interfaces are limited in their capabilities for recording symptoms and delivering effective treatments. This restricts the ability to understand the biological causes of these disorders and develop targeted therapies.
Solution
Integral Neurotechnologies is developing a miniaturized, implanted deep-brain interface designed for patients with severe neurological and psychiatric conditions. This device offers advanced capabilities for both recording and modulating neural activity, enabling comprehensive monitoring of patient symptoms. By providing a unique platform for discovery, the technology aims to significantly improve the understanding of brain disorders and facilitate the development of a wider range of more effective treatments. The focus is on ambitious engineering and rapid development to address the urgent needs of patients.
Target Audience
The primary target audience includes patients with severe neurological and psychiatric disorders who require advanced monitoring and therapeutic intervention, as well as researchers seeking to understand the biological underpinnings of these conditions.
Features
- Miniaturized implantable device for deep-brain interfacing
- High-resolution recording of neural activity
- Precise modulation of targeted brain regions
- Continuous monitoring of patient symptoms